Efficacy and Safety Study of Certolizumab Pegol (CZP) Versus Active Comparator and Placebo in Subjects With Plaque Psoriasis (PSO)
Public ClinicalTrials.gov record NCT02346240. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled Study Followed by a Placebo-Controlled Maintenance Period and Open-Label Follow-Up to Evaluate the Efficacy and Safety of Certolizumab Pegol in Subjects With Moderate to Severe Chronic Plaque Psoriasis
Study identification
- NCT ID
- NCT02346240
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- UCB Biopharma S.P.R.L.
- Industry
- Enrollment
- 559 participants
Conditions and interventions
Conditions
Interventions
- Certolizumab Pegol Biological
- Etanercept Biological
- Placebo Other
Biological · Other
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 10, 2015
- Primary completion
- Mar 21, 2016
- Completion
- Dec 16, 2018
- Last update posted
- Jul 15, 2021
2015 – 2018
United States locations
- U.S. sites
- 19
- U.S. states
- 13
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Ps0003 317 | Mobile | Alabama | 36608 | — |
| Ps0003 306 | Little Rock | Arkansas | 72204 | — |
| Ps0003 301 | Beverly Hills | California | 90212 | — |
| Ps0003 307 | Los Angeles | California | 90045 | — |
| Ps0003 405 | San Diego | California | 92123 | — |
| Ps0003 316 | Washington D.C. | District of Columbia | 20037 | — |
| Ps0003 304 | West Palm Beach | Florida | 33409 | — |
| Ps0003 302 | Springfield | Illinois | 62703 | — |
| Ps0003 313 | West Dundee | Illinois | 60118 | — |
| Ps0003 310 | Indianapolis | Indiana | 46256 | — |
| Ps0003 400 | Henderson | Nevada | 89052 | — |
| Ps0003 319 | Verona | New Jersey | 07044-29 | — |
| Ps0003 404 | Buffalo | New York | 14203 | — |
| Ps0003 407 | Portland | Oregon | 97223 | — |
| Ps0003 309 | Johnston | Rhode Island | 02919 | — |
| Ps0003 401 | Dallas | Texas | 75246 | — |
| Ps0003 403 | Houston | Texas | 77065 | — |
| Ps0003 406 | San Antonio | Texas | 78213 | — |
| Ps0003 311 | Webster | Texas | 77598 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 51 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02346240, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 15, 2021 · Synced May 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02346240 live on ClinicalTrials.gov.